Patent: 9,574,010
✉ Email this page to a colleague
Summary for Patent: 9,574,010
Title: | Stable heterodimeric antibody design with mutations in the Fc domain |
Abstract: | The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics. |
Inventor(s): | Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) |
Assignee: | Zymeworks Inc. (Vancouver, CA) |
Application Number: | 13/668,098 |
Patent Claims: | see list of patent claims |
Details for Patent 9,574,010
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-11-04 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-11-04 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2031-11-04 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2031-11-04 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2031-11-04 |
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2031-11-04 |
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | ⤷ Try a Trial | 2031-11-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |